VEGFA and neoplasm: In mouse models, administration of the angiogenesis-targeted anti-VEGF antibody and paclitaxel led to treatment resistance, but the addition of a CSF-1R inhibitor (CSF-1 regulates macrophage survival and migration) restored sensitivity to anti-VEGF therapy and decreased macrophage infiltration and tumor burden (59).